One could describe Mary Costello as a world-class expert in international marketing, business initiatives, and leadership, with a background in patient advocacy, global marketing initiatives, and clinical trial solutions—and one would be correct. Her impressive career includes roles such as Head of Site and Investigator Network at Medable, Vice President of Clinic Development & Patient Advocacy at Elligo Health Research, and Vice President/Global Director of Marketing at leading life science organizations like eClinical Solutions, Fisher Clinical Services, and Covance.But Mary is not just an accomplished leader; she’s also a skilled question-asker, with the unique ability to construct innovative solutions from complex subjects. Join Mary and host Colin Miller on a question-and-answer filled episode of Fractals, where they hypothesize about connectivity in today’s life sciences industry, including, but certainly not limited to: The evolution of patient recruitment and the two key factors driving change: the accessibility of data-driven decisions and the rise of digital healthcare.Our early understanding of how AI can bridge essential gaps in clinical and marketing areas by automating mundane tasks that enhance patient engagement, such as delivering marketing messages, building trust, and prompting action.The limitations of the "one-and-done" model in patient care, emphasizing the need for flexibility and connectivity in inclusive, accessible treatment to achieve sustainable success.The foundational role of pre-competitive collaboration and widespread education in advancing life sciences and improving human lives. Listen to Fractals: Life Science Conversations via your preferred podcast service, and contact us today to learn more.

When launching a product or service, it all comes down to one essential question: what problem are you really trying to solve?In this SNiP, global marketing strategist and life science industry expert Mary Costello breaks down the essential steps to uncovering the root causes of a company’s marketing challenges. From the importance of understanding buyer behavior to the consequences of burning through time and money without validating demand, Mary shares the realities of marketing that every life science startup, large-scale company, and clinical research organization must face.With practical advice on avoiding costly mistakes and insight into aligning your strategy with customer needs, Mary’s approach is as actionable as it is insightful—and she delivers it in under 8 minutes.Tune in now, and subscribe to Fractals to be the first to hear Mary’s upcoming full-length episode.

With expertise in pharmacology, due diligence, strategic planning, peptide-based therapeutics, and beyond, it’s no wonder that Bracken co-founder and Managing Partner Dr. Jim Gilligan is also leading the way in therapeutic psychedelic drug development. With 35+ years of expertise, Jim’s cutting-edge work is reshaping our approach to mental health and chronic pain management. This integrated approach combines clinical insight with scientific innovation, turning psychedelic research into practical, impactful treatments.In this episode of Fractals, join Jim and host Colin Miller as they explore:The groundbreaking science behind psilocybin-assisted therapy and its potential to revolutionize mental health and chronic pain treatment.The essential role of clinical trials in validating psychedelic drugs, and insights into navigating the complex regulatory landscape.Strategies for biotech startups to attract investors, blending robust clinical data with a compelling commercial strategy.How investing in the future of science means supporting areas with high clinical impact, sustainable healthcare solutions, transformative research, and the growth of young scientists.Listen to Fractals: Life Science Conversations via your preferred podcast service, and contact us today to learn more about working with Jim and Bracken’s team of expert consultants. 

Imagine a world where therapeutic psychedelic drugs aren’t just visionary, but practical, scalable, and scientifically sound. That world is almost here. In this SNiP, Bracken Co-Founder and Managing Partner Jim Gilligan, PhD takes us behind the scenes of his groundbreaking advances in psilocybin treatment. Jim reveals how an integrated approach can turn bold ideas into commercial reality, with insights on regulating psilocin for therapy and advice for bringing revolutionary, patient-focused solutions to market—all in under 7 minutes.Tune in now, and subscribe to Fractals for Jim’s full episode, releasing October 3rd, for a deep dive into psychedelic medicine, biopharma startups, M&A, and more.

Medical doctor, digital software and hardware programmer, and professional trainer—Bracken Senior Partner Paul Martinetti continues to defy a singular career path. Paul exemplifies an integrated approach: leading collaborative efforts to invent, build, and implement innovative solutions, such as an online photo-based acne severity consensus tool and a clinical study t-shirt, setting new industry standards, and leveraging multimedia technology development to support oncology survivors in clinical trial settings. Paul utilizes his medical background, AI, and programming skills to problem-solve in both clinical and cyber spaces. In this episode of Fractals, join Paul and host Colin Miller as they explore:The importance of listening closely at the initial stage of problem-solving and the need for collaborative efforts to achieve solutions,Why embracing developing technologies is essential and the significance of using them as tools rather than being controlled by them, with a primary principle of "do no harm”,How taking on diverse roles throughout a career fosters growth and out-of-the-box thinking to solve problems, and,The necessity of forward-thinking and creating enduring messaging and media in a rapidly evolving world.

Start your project early, communicate with regulatory bodies often, and begin with the validation in mind—that’s Dr. Paul Martinetti’s starting advice for aspiring life scientists looking to bridge the gap between technology and healthcare. Tune into our latest SNiP, a special segment of Fractals Life Science Conversations, to hear more. Listen now, and stay tuned for the full episode of Fractals, releasing later this month.

When you think about “people and platforms”, does “data analytics” come to mind? In this SNiP, our new special recurring segment of Fractals: Life Science Conversations, Bracken Senior Partner Ben Mitchell tells us exactly why data analytics, people, and platforms are the foundations for which life sciences thrives. Tune in to learn more about the importance of adopting an integrated approach to your data analytics; Not only is data essential to business—it's equally fundamental to the life sciences industry at large. 

It's not just about the deal—it's about what happens next. In this episode of SNiPS, Bracken COO Dawn Flitcraft uncovers the surprising reactions and feelings of life science CEOs after their companies are acquired. Learn how having an integration leader and providing executive support can make all the difference. Listen now to hear how 95% of the time, these transitions lead to success.

Yunu's co-founder and CEO, Jeff Sorenson, recognizes the pivotal role marketing plays in the life sciences sector, spanning brand communication and customer awareness. By prioritizing investments in streamlined user experience (UX), data-informed sales strategies, and cohesive messaging, the significance of marketing can reach new heights—and your company can reach a global audience. Hear more of Jeff’s insights in conversation with Colin Miller in this SNiP, a special segment of Fractals: Life Science Conversations, streaming now.Listen to Fractals: Life Science Conversations via your preferred podcast service, and contact us today to learn more.

With a proven track record of transforming clinical trial imaging data and workflows, Fractals guest Jeff Sorenson knows what it takes to eliminate delays and accelerate results in the life sciences industry. As the co-founder and CEO of Yunu, Jeff collaborates with life science companies and cancer centers to revolutionize clinical trials, achieving faster time-to-market for sponsors and CROs. Join Jeff and host Colin Miller for a conversation on the world of medical imaging, including:Automating AI in clinical imaging to alleviate staffing shortages and redirect focus to patient care,  Emphasizing the value of integrated workflows and comprehensive data management for effective success stories in healthcare, particularly in medical imaging applications,Prioritizing integrated troubleshooting over straightforward product development to ensure continuous innovation, and, Leveraging multimodal clinical data to unlock new potential across clinical trials, decision support, and beyond. 

In this debut episode of SNiPs, a special recurring segment of Fractals: Life Science Conversations, Alexander (Sandy) J.B. McEwan, MB, MSc, FRCPC, Bracken’s in-house expert in nuclear medicine, returns to the audio stage. Dr. McEwan, who has served as Past President of SNMMI, Chief Medical Officer at Ariceum, and Vice President of Radiopharmaceuticals at Ipsen, brings a wealth of experience and academic knowledge. He and host Colin Miller discuss the anticipated technological advancements in the radiopharmaceutical field to take place over the next decade. Topics include the importance of dosimetry, the "external beam paradigm," treatment options, AI in clinical trials and medical imaging, and more—all in under 6 minutes. This SNiP is a small segment of a larger conversation—to learn more about the necessity of nuclear medicine, tune into Dr. Sandy McEwan's full-length episode now.

Data analytics expert, systems and operations specialist, optimization and automation wizard—that’s our Senior Partner, Ben Mitchell. Previously the founder of tech startup The Brite Mind, then Vice President of Operations and Information Services and Analytics here at Bracken, Ben now works in a consulting capacity. Join Ben and host Colin Miller on this episode of Fractals: Life Science Conversations to discuss innovation across life science technology and data analytics, including:The evolution of digital advertising and growth marketing towards empowering clients through technology,The pivotal role of data as a cornerstone in life sciences and the importance of an integrated approach in both human interaction and platform creation,The construction of analytics and data structures for problem-solving, and how tailored data analytics in life sciences can unlock vast potential and opportunities, and,The essential guideposts for successful data analytics projects, including feasibility, team dynamics, stakeholder buy-in, and robust project planning.

A professional problem solver—that’s our Senior Partner, Marybeth Profrock. With a wealth of experience in accelerating growth for life sciences and digital health companies, Marybeth thrives on crafting innovative marketing solutions. Throughout her career, she’s specialized in digital innovation, B2B marketing, and content strategy, driving tangible results through analytical problem solving and meticulous execution. Tune in to the latest episode of Fractals to hear Marybeth and host Colin Miller turn the essential questions of life sciences marketing on their head, including:The importance of a comprehensive assessment and understanding of client requirements in crafting effective marketing or business strategies.Why analyzing the elements of effective marketing begins with addressing any problems at the root and how often foundational components quickly become critical to overall success.What the future potential of generative AI is within marketing strategies, a future contingent upon asking the right questions, andWhy the backbone of any client project is continuous communication (and why it’s critical for any successful one). 

Head of Regulatory Affairs, FDA communications expert, and Managing Partner: That’s Liz Bloss. Join us for this episode of Fractals: Life Science Conversations as we welcome Liz to the program. Liz brings a wealth of experience, from formulating early IND submission strategies to guiding companies through the complexities of NDA preparations. With a sharp focus on FDA communications and meeting readiness, Liz adeptly navigates milestone gatherings crucial for development program success. Her proficiency extends to maneuvering orphan drug submissions, providing US Agent support, and delivering invaluable regulatory feedback. Tune in to get the inside scoop on all thing regulatory from Liz, including:The significance of attentive listening and strategic pauses in achieving regulatory goals and fostering meaningful connections.Establishing communication channels between scientific and regulatory spheres to forge pathways with FDA or regulatory bodies.Understanding how regulatory affairs transcends paperwork and emphasizes the need for innovative interpretation and thinking outside traditional confines.Recognizing the importance of cultivating personal relationships, networking opportunities, and empowering women in the life sciences industry to foster an inclusive environment that embraces diverse perspectives.

Groundbreaking science and entrepreneurial spirit go hand-in-hand with our latest guest: osteoarthritis expert and Senior Partner, Jon Larkin. With over two decades of research in pharma and biotech giants as well as his own startup, Jon shares insights on pioneering osteoarthritis therapies, leading clinical development efforts, and shaping the world of biopharma in academics, industry, and consortia alike. In this episode of Fractals, join Jon and host Colin Miller for valuable insights on:How the dynamic evolution of osteoarthritis drug development has permeated the industry, and its impact on treatment strategies. The symbiotic relationship between leadership, collaboration, and success in healthcare.The intricacies of navigating critical decision points and regulatory challenges to advance clinical studies effectively, and...Unveiling the origins of drugs, from academia to industry, and the pivotal role of consortia in innovation.

Former Chief Medical Officer, Vice President of Nuclear Medicine, and long-time academic physician—that's our in-house nuclear medicine expert, Dr. Sandy McEwan. From research and publications in the academic space to hands-on development of novel SRTs, Sandy’s expertise is as developed as it is broad. Join Sandy and host Colin Miller on this episode of Fractals to hear key insights on: The evolving landscape of nuclear medicine, radioisotope therapy, and radiopharmaceuticals in light of technological advancements, and a glimpse into their future. Defining success metrics in nuclear medicine and how they are influenced by treatment modalities.The collaborative potential between industry and academia in advancing groundbreaking treatments and introducing new options for patients.The importance of prioritizing patient-centered approaches in the advancement of radiopharmaceutical therapies. 

At the forefront of digital healthcare technology, patient-centric initiatives, financial oversight, and integrated due diligence—that’s our accomplished Senior Partner, Martin Collyer. From orchestrating financial balance to crafting comprehensive due diligence strategies and addressing the pivotal need for personalized patient engagement in modern healthcare, Martin has consistently excelled at driving success with real results.Join Martin and host Colin Miller in this episode of Fractals: Life Science Conversations to glean crucial insights on:The imperative of patient-centric initiatives in the ever-evolving digital healthcare landscape,The comprehensive view of opportunities and risks behind successful healthcare due diligence,The metrics and benchmarks defining effectiveness in the front-facing side of life sciences, andThe significance of treating each patient’s journey and experience on a personalized scale for positive and succinct results.Tune in to Fractals: Life Science Conversations on your preferred podcast platform for this and other valuable episodes.

Nick Spring is no stranger to the complexity of both building and sustaining business across the life sciences. In fact, from the wide-ranging topic of due diligence to the hands-on work of creating diagnostic products and therapeutic solutions, Nick has his finger on the pulse on how to thrive in the life sciences. Join Nick and host Colin Miller on this episode of Fractals: Life Science Conversations to learn about strategizing for success, with key insights on:  The 4 steps for fruitful tactical execution in biopharmaceutical business.The importance of “planning the work, then working the plan”: why a structured approach from the beginning works across the industry.Why successful due diligence goes beyond mergers and acquisitions.How the complexity of AI and machine learning will shape the biopharmaceutical industry, from microbiology to imaging to diagnostic capabilities. 

Andrew Beck’s impressive career has spanned various niches across the radiopharmaceutical development sphere. From utilizing a holistic path for building a successful strategy to the key pairing of pharmaceutical sales and patient advocacy, Andrew understands that an integrated approach is paramount to success. On this episode of Fractals: The Life Sciences Questionnaire, dig deeper into radiopharmaceutical development and hear Andrew’s key insights on:What the radiopharmaceutical “unk-unk” is (and how to navigate running into associated roadblocks),Why the simple availability of a product doesn’t necessarily indicate adoption of treatment,How beginning with the end in mind is key critical to building a holistic and successful business and/or commercialization strategy, Why and how patient advocacy will continue to advance both standard of care and collaborative business strategy. 

Dr. Deepak Behera is no stranger to the puzzles of radiopharmaceutical development and life sciences marketing. That’s why, on this episode of Fractals: The Life Sciences Questionnaire, he shared his perspectives on holistic clinical development strategies and the importance of breaking siloed communication, as well as: Why pairing the needs of patients with clinical development strategy is essential for driving positive health outcomesDiversifying accessibility to clinical trials through community physician and hospital participationIntegrated approaches to marketing and business strategy, and risk mitigationBreaking barriers in clinical development, and the importance of soft skills